Preclinical mice and rat model generation

Customised gene engineering for translational research

CIPHE's genetic engineering and mouse transgenesis platform brings together a multidisciplinary team of immunologists, genetic engineers and research scientists. Working under ISO 9001 certified quality standards, the team uses advanced technologies to generate highly accurate models for the validation of gene mechanisms in both normal and pathological conditions such as infection, inflammation and cancer and all other mice models you need. This structured approach enables CIPHE to meet the diverse needs of academic and industrial partners.

Head of Platform: Frédéric Fiore, PhD

Team & experts

+15 years

of experience

R&D

seamlessly conducted

+600

preclinical models delivered

Proprietary & innovative technologies for custom animal model solutions for academics & industry worldwide

Traditional development of genetically engineered research models takes 4 to 11 months, depending on project complexity and technical approach. To accelerate this process, CIPHE leverages cutting-edge genetic engineering and proprietary technologies to deliver customized mouse and rat models.
CIPHE develops custom mouse and rat models that closely mimic human diseases in immunology, autoimmunity, rare diseases, inflammation, infection, cancer and neurology. These models are essential for studying disease mechanisms, assessing gene function, and accelerating drug development. By integrating omics sciences with advanced computational tools, CIPHE enhances the understanding of human biology in both normal and pathological conditions. CIPHE also conducts its own R&D to continuously expand its portfolio of preclinical models.

As a founding member of PHENOMIN and CELPHEDIA, CIPHE plays a key role in the advancement of functional genomics and preclinical research. We specialize in the generation of customized mouse and rat models that closely mimic human disease, supporting research across multiple therapeutic areas. Through our participation in international consortia such as EMMA and Infrafrontier, we contribute to the generation, maintenance and distribution of genetically engineered mouse models. In addition, our participation in IMPC, a global initiative to create a comprehensive functional encyclopedia of mammalian genes, further strengthens our capabilities. These efforts enable us to provide innovative models that accelerate the understanding of disease mechanisms, gene function and drug development.

Collaborative efforts in mouse and rat model generation

CIPHE offers a comprehensive suite of services for the creation and validation of custom preclinical models, providing advanced tools for the genetic validation and characterization of human diseases and ensuring accurate representation of disease mechanisms and therapeutic targets. Our services include :

Zygote Genome Editing: We offer advanced expertise in CRISPR-Cas9-mediated genome editing and precise genetic targeting to introduce point mutations or small DNA fragments, facilitating the rapid development of disease models. For the knock-in of larger DNA sequences, we provide an AAV-assisted CRISPR-Cas9 approach. All genetic modifications are thoroughly validated, including off-target analysis in heterozygous F1 animals.
Homologous Recombination in Mouse Embryonic Stem Cells (mESCs): Depending on the size of the insert or project-specific requirements, we perform gene targeting in mouse embryonic stem cells using homologous recombination. Genetic alterations are validated, and chimeric animals are generated to establish heterozygous F1 lines.
Transgenesis by Microinjection or Electroporation: For all genetically modified models, we deliver full and personalized support: selection of heterozygous founders, design and implementation of genotyping protocols, sperm cryopreservation of the established lines, and global shipment of SOPF-certified models. We also offer comprehensive animal care services, including hosting, breeding, and cohort generation for research-ready models.

Integrated gene analysis & validation

CIPHE specializes in employing the latest technologies to create custom preclinical models that replicate human diseases with high accuracy.

Knockout and Knock-in models: Using ES cell-based or CRISPR/Cas9 technologies for targeted gene modifications.
Embryo-based CRISPR/Cas9 models: Allowing rapid and efficient genome editing with minimal time investment.
Homologous recombination techniques: Providing precise gene targeting and validation for experimental purposes. Mainly engaged in large Knock-in cassettes.

Advanced genome modification capabilities

Our state-of-the-art animal facility meets strict health control regulations (EOPS-certified) and operates under ISO 9001-certified quality standards, ensuring reliable and reproducible preclinical models.